MX348282B - Formulaciones farmaceuticas de liberacion controlada de nitazoxanida. - Google Patents

Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.

Info

Publication number
MX348282B
MX348282B MX2011008530A MX2011008530A MX348282B MX 348282 B MX348282 B MX 348282B MX 2011008530 A MX2011008530 A MX 2011008530A MX 2011008530 A MX2011008530 A MX 2011008530A MX 348282 B MX348282 B MX 348282B
Authority
MX
Mexico
Prior art keywords
nitazoxanide
controlled release
pharmaceutical formulations
release pharmaceutical
analogue
Prior art date
Application number
MX2011008530A
Other languages
English (en)
Other versions
MX2011008530A (es
Inventor
Rossignol * Jean-Francois
Ayers Marc
Original Assignee
Romark Laboratories L C *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Romark Laboratories L C * filed Critical Romark Laboratories L C *
Publication of MX2011008530A publication Critical patent/MX2011008530A/es
Publication of MX348282B publication Critical patent/MX348282B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se proporcionan formulaciones de dosificación sólida de nitazoxanida, o un análogo de nitazoxanida que comprenden una porción de liberación controlada y una porción de liberación inmediata. La composición farmacéutica está típicamente en la forma de una forma de dosificación oral sólida de dos capas que comprende (a) una primera capa que comprende una primera cantidad de nitazoxanida o análogo de la misma en una formulación de liberación controlada, y (b) una segunda capa que comprende una segunda cantidad de nitazoxanida o un análogo de la misma en una formulación de liberación inmediata. También se proporciona el método de uso de las formulaciones en el tratamiento de la hepatitis C.
MX2011008530A 2009-02-13 2010-02-12 Formulaciones farmaceuticas de liberacion controlada de nitazoxanida. MX348282B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20228509P 2009-02-13 2009-02-13
PCT/US2010/024000 WO2010093854A1 (en) 2009-02-13 2010-02-12 Controlled release pharmaceutical formulations of nitazoxanide

Publications (2)

Publication Number Publication Date
MX2011008530A MX2011008530A (es) 2011-10-14
MX348282B true MX348282B (es) 2017-06-05

Family

ID=42560126

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006915A MX381895B (es) 2009-02-13 2010-02-12 Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.
MX2011008530A MX348282B (es) 2009-02-13 2010-02-12 Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017006915A MX381895B (es) 2009-02-13 2010-02-12 Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.

Country Status (23)

Country Link
US (5) US8524278B2 (es)
EP (1) EP2395840B1 (es)
JP (3) JP5726766B2 (es)
KR (1) KR101697800B1 (es)
CN (2) CN107260695A (es)
AU (3) AU2010213678B2 (es)
BR (1) BRPI1007945C8 (es)
CA (1) CA2752233C (es)
CO (1) CO6501159A2 (es)
CY (1) CY1123162T1 (es)
DK (1) DK2395840T3 (es)
EA (1) EA029018B1 (es)
ES (1) ES2797493T3 (es)
HR (1) HRP20201055T1 (es)
HU (1) HUE049501T2 (es)
IL (1) IL214624A0 (es)
LT (1) LT2395840T (es)
MX (2) MX381895B (es)
PL (1) PL2395840T3 (es)
PT (1) PT2395840T (es)
SI (1) SI2395840T1 (es)
UA (1) UA107564C2 (es)
WO (1) WO2010093854A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2636527C (en) * 2006-01-09 2016-05-17 Romark Laboratories, L.C. Viral hepatitis treatment
SI2395840T1 (sl) 2009-02-13 2020-08-31 Romark Laboratories, L.C. Farmacevtske formulacije nitazoksanida z nadzorovanim sproščanjem
WO2013110975A1 (es) * 2012-01-27 2013-08-01 Siegfried Rhein S.A. De C.V. Composición de nitazoxanida mejorada y proceso para prepararla
CA2864858A1 (en) * 2012-02-20 2013-08-29 Lupin Limited Bilayer tablet of dronedarone
KR101639692B1 (ko) * 2013-12-13 2016-07-14 제일약품주식회사 2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물
MX2017006083A (es) 2014-11-11 2017-11-08 Romark Laboratories Lc Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma.
PT3436074T (pt) 2016-03-31 2020-08-21 Romark Laboratories Lc Compostos tiazolida para tratamento de infeções virais
KR102410951B1 (ko) * 2016-04-11 2022-06-20 장피트 담즙정체성 및 섬유증 질환의 치료 방법
US10905680B2 (en) * 2016-04-11 2021-02-02 Genfit Methods of treatment for cholestatic and fibrotic diseases
EA201992116A1 (ru) * 2017-03-08 2020-01-29 СИНРКС ФАРМА, ЭлЭлСи Фармацевтические составы флороглюцинола и триметилфлороглюцинола
WO2018167103A1 (en) * 2017-03-13 2018-09-20 Genfit Pharmaceutical compositions for combination therapy
WO2018195035A1 (en) 2017-04-18 2018-10-25 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase a3
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
WO2018230713A1 (ja) * 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
CN108524460B (zh) * 2018-05-14 2021-01-01 佛山市南海东方澳龙制药有限公司 烯啶虫胺双层片
WO2019241376A1 (en) 2018-06-14 2019-12-19 The Trustees Of Columbia University In The City Of New York Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
CN110025621A (zh) * 2019-03-13 2019-07-19 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 替唑尼特和硝唑尼特在制备抗炎药物中的应用
CN111012788B (zh) * 2019-12-12 2021-01-15 武汉职业技术学院 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
WO2021125824A1 (ko) * 2019-12-19 2021-06-24 (주)셀트리온 시벤졸린 또는 이의 염을 포함하는 약학 제형
US20230303504A1 (en) 2020-07-20 2023-09-28 Romark Laboratories, L.C. Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
MX2023002208A (es) 2020-08-24 2023-05-17 Romark Laboratories Lc Uso de tiazolidas contra los coronavirus.
WO2022130406A1 (en) * 2020-12-15 2022-06-23 Cipla Limited Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease
WO2023058046A1 (en) 2021-10-05 2023-04-13 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) An improved process for the preparation of nitazoxanide and intermediates thereof
CN114259492A (zh) * 2021-12-21 2022-04-01 中以海德人工智能药物研发股份有限公司 硝唑尼特在治疗乙肝中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
JPH06316517A (ja) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5578621A (en) 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
CN100515420C (zh) * 1997-05-07 2009-07-22 罗马克实验室有限公司 脱乙酰基硝噻醋柳胺和硝噻醋柳胺的药用组合物
US5948440A (en) 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
MXPA01004381A (es) 1998-11-02 2005-09-08 Elan Corp Plc Composicion de multiparticulado de liberacion modificada.
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
JP4637338B2 (ja) * 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
ATE361060T1 (de) 2000-09-29 2007-05-15 Solvay Pharm Bv Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
US7074417B2 (en) 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
NZ532096A (en) * 2001-09-28 2006-10-27 Mcneil Ppc Inc Dosage forms having an inner core and outer shell with different shapes
BR0213079A (pt) 2001-09-28 2004-11-09 Sun Pharmaceutical Ind Ltd Forma de dosagem para o tratamento da diabetes mellitus
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
PE20050335A1 (es) 2003-08-07 2005-06-01 Sb Pharmco Inc Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion
GB0319874D0 (en) * 2003-08-22 2003-09-24 Glaxo Group Ltd Novel formulation
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
AU2006235490A1 (en) 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
CA2636527C (en) * 2006-01-09 2016-05-17 Romark Laboratories, L.C. Viral hepatitis treatment
JP2006335771A (ja) * 2006-09-22 2006-12-14 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
US20080299188A1 (en) * 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug
US20080286344A1 (en) * 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
ES2550755T3 (es) 2007-08-03 2015-11-12 Romark Laboratories, L.C. Compuestos de tiazolida sustituidos con alquilsulfonilo
SI2395840T1 (sl) * 2009-02-13 2020-08-31 Romark Laboratories, L.C. Farmacevtske formulacije nitazoksanida z nadzorovanim sproščanjem

Also Published As

Publication number Publication date
CA2752233A1 (en) 2010-08-19
SI2395840T1 (sl) 2020-08-31
US8524278B2 (en) 2013-09-03
US20160243087A1 (en) 2016-08-25
KR101697800B1 (ko) 2017-01-18
ES2797493T3 (es) 2020-12-02
CN102395276A (zh) 2012-03-28
HUE049501T2 (hu) 2020-09-28
EP2395840A1 (en) 2011-12-21
US9827227B2 (en) 2017-11-28
AU2010213678B2 (en) 2015-11-26
EP2395840B1 (en) 2020-04-15
HRP20201055T1 (hr) 2020-10-30
PT2395840T (pt) 2020-07-06
MX2011008530A (es) 2011-10-14
US20190321338A1 (en) 2019-10-24
US20100209505A1 (en) 2010-08-19
LT2395840T (lt) 2020-07-10
US20180085353A1 (en) 2018-03-29
DK2395840T3 (da) 2020-06-08
US9351937B2 (en) 2016-05-31
AU2010213678A1 (en) 2011-09-01
JP6491174B2 (ja) 2019-03-27
KR20120008024A (ko) 2012-01-25
BRPI1007945C8 (pt) 2021-05-25
BRPI1007945C1 (pt) 2020-09-01
BRPI1007945B8 (pt) 2020-08-18
PL2395840T3 (pl) 2020-09-07
MX381895B (es) 2025-03-13
AU2017203148B2 (en) 2018-08-09
UA107564C2 (uk) 2015-01-26
CY1123162T1 (el) 2021-10-29
US11426388B2 (en) 2022-08-30
AU2016200971B2 (en) 2017-02-23
CO6501159A2 (es) 2012-08-15
EA029018B1 (ru) 2018-01-31
EP2395840A4 (en) 2013-12-25
BRPI1007945B1 (pt) 2020-08-04
JP2017061561A (ja) 2017-03-30
JP2015143258A (ja) 2015-08-06
JP6117845B2 (ja) 2017-04-19
US10383855B2 (en) 2019-08-20
AU2017203148A1 (en) 2017-06-01
JP5726766B2 (ja) 2015-06-03
WO2010093854A1 (en) 2010-08-19
EA201190127A1 (ru) 2012-03-30
CA2752233C (en) 2017-01-03
JP2012518002A (ja) 2012-08-09
US20140065215A1 (en) 2014-03-06
IL214624A0 (en) 2011-09-27
CN107260695A (zh) 2017-10-20
BRPI1007945A2 (pt) 2015-09-01
AU2016200971A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
MX348282B (es) Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
WO2007149406A8 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
AR082091A1 (es) Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion
WO2007016563A3 (en) Alcohol resistant pharmaceutical formulations
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
TW200621317A (en) Pharmaceutical composition
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
CO6620043A2 (es) Procedimiento de preparación de composiciones famacéuticas destinadas a la administración por vía oral que comprende uno o varios principios activos y las composiciones que las comprenden
MY145790A (en) Composition
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
MX336209B (es) Suministro de formulaciones secas de octreótido.
NO20091954L (no) Anvendelse av ostradiolvalerat eller 17ß-ostradil i kombinasjon med dienogest for oral terapi for opprettholdelse og/eller okning av kvinnelig libido
PL2252290T3 (pl) Kompozycja farmaceutyczna do zastosowania w leczeniu i/lub zapobieganiu chorobom kostno-stawowym
MX2009010989A (es) Composiciones farmaceuticas liofilizadas y metodos de obtener y usar las mismas.
EA201290734A1 (ru) Рифаксимин в форме порошка, способ его получения и композиции контролируемого высвобождения, содержащие указанный рифаксимин, полезные для достижения длительного эффекта
WO2014106846A3 (en) Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
IL202111A0 (en) Formulations for the oral administration of therapeutic agents and related methods
WO2008113901A3 (fr) Composition à libération prolongée de lévétiracetam et procédé de préparation.
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
MX2010009848A (es) Composiciones para el suministro especifico en sitio de imatinib y metodos de uso.
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
DK1880718T3 (da) Farmaceutisk præparat til oral administration med kontrolleret frigivelse af aktivt stof i tyndtarmen og fremgangsmåde til fremstilling deraf
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
EA200702102A1 (ru) Пластинки, содержащие стероидные гормоны

Legal Events

Date Code Title Description
FG Grant or registration